IBEX Technologies Inc. (IBT.V)
| Previous Close | 0.4650 |
| Open | 0.4600 |
| Bid | 0.4400 x 0 |
| Ask | 0.4750 x 0 |
| Day's Range | 0.4600 - 0.4600 |
| 52 Week Range | 0.2700 - 0.6000 |
| Volume | |
| Avg. Volume | 14,317 |
| Market Cap | 11.419M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | 7.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022
MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022. “We are pleased with the continued growth in sales, driven by strong sales of heparinase-based products, as well as by the sales of aryl-acyl amidase, a product used in tests for acetaminophen poisoning; and also with the continued strengthening of the Company’s balance sheet” said Paul Baehr, IBEX P
- GlobeNewswire
IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2022
MONTRÉAL, March 17, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2022. “We are pleased with the continued growth driven by strong sales of heparinase-based products,” said Paul Baehr, IBEX President & CEO “and with the continued strengthening of the Company’s balance sheet. We foresee the trend to continue for the balance of the fiscal year.” Note: All figures are in Canadian
- GlobeNewswire
IBEX Announces Results of Annual Meeting
MONTREAL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce that all six nominees listed in its management proxy circular dated January 4, 2022 were re-elected as directors at the Company’s annual and special meeting held today in Montreal. At the meeting, shareholders also approved a resolution ratifying, confirming and approving the “reload” of 527,008 common shares under IBEX’s Incentive Stock Option Plan and a resolut
